Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
7 hedge funds and large institutions have $157K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
52% less capital invested
Capital invested by funds: $328K → $157K (-$171K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$397 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIA
Compass Ion Advisors
Conshohocken,
Pennsylvania
|
-$1.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $54K | – | – | – |
|
|
PA
2
Perceptive Advisors
New York
| $54K | – | – | – |
|
|
SFM
3
Sphera Funds Management
Tel Aviv,
Israel
| $17K | – | – | – |
|
|
MWNA
4
Marshall Wace North America
New York
| $16K | – | – | – |
|
|
PC
5
PointState Capital
New York
| $12K | – | – | – |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $3K | +$397 | +2,086 | +10% |
|
|
CIA
7
Compass Ion Advisors
Conshohocken,
Pennsylvania
| $1K | -$1.9K | -10,000 | -50% |
|
OTLKW Hedge Fund Activity: Q3 2020 in Review
7 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q3 2020, worth a combined $157K — down 52% from $328K a quarter earlier.
Fund positioning in OTLKW was balanced in Q3 2020: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $397. The largest seller was Compass Ion Advisors, cutting an estimated $1.9K.
- 7 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $157K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q3 2020, down 52% quarter-over-quarter.
- 0 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q3 2020 and 0 closed out.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q3 2020 was Susquehanna International Group, an estimated $397 added.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q3 2020 was Compass Ion Advisors, an estimated $1.9K sold.
Based on aggregated 13F filings for Q3 2020.